Halozyme Recruits Industry Veteran Jim Daly to Board of Directors

Halozyme CEO Dr. Helen Torley highlighted Daly’s track record in scaling blockbuster therapies as a critical asset for the firm’s current phase of growth. Daly, who previously served on the company’s board, brings extensive experience from senior roles at Incyte Corporation, Amgen, and GlaxoSmithKline. His appointment aligns with Halozyme’s strategy to shift more biologic treatments from clinical settings to at-home administration.

Daly currently holds board positions at Acadia Pharmaceuticals, Madrigal Pharmaceuticals, and Cytokinetics. In his new capacity at Halozyme, he will oversee the expansion of the company’s drug delivery portfolio, which now includes the hyperconcentration technologies Hypercon and Aerocon. These tools are designed to reduce injection volumes, aiming to simplify treatment regimens for patients worldwide.